Cue Biopharma is trading 5.34% down at $29.25 now, with no identified company-specific announcement or reliable late-breaking catalyst explaining the after-hours decline.
- The decline follows a volatile September 22 session.
- September 20 CUE-221 Phase 2 data showed statistically significant efficacy and favorable safety findings, but that positive news does not directly explain the September 22 after-hours drop.